Replimune Group (NASDAQ:REPL) Given New $22.00 Price Target at Piper Sandler

Replimune Group (NASDAQ:REPL - Free Report) had its price objective raised by Piper Sandler from $14.00 to $22.00 in a report released on Monday morning,Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

Several other equities analysts have also recently issued reports on the stock. HC Wainwright lifted their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. increased their price objective on Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Replimune Group has an average rating of "Buy" and an average target price of $19.75.

Replimune Group Stock Performance

REPL traded up $0.06 during trading on Monday, reaching $9.63. The company's stock had a trading volume of 1,491,784 shares, compared to its average volume of 946,501. Replimune Group has a 52-week low of $4.93 and a 52-week high of $17.00. The company's fifty day moving average price is $8.35 and its 200-day moving average price is $11.06. The company has a market capitalization of $742.35 million, a price-to-earnings ratio of -3.14 and a beta of 0.68. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its quarterly earnings results on Thursday, May 22nd. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same quarter in the prior year, the business posted ($0.25) earnings per share. On average, equities analysts forecast that Replimune Group will post -2.97 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CAO Andrew Schwendenman sold 3,287 shares of the stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.05, for a total value of $26,460.35. Following the sale, the chief accounting officer now directly owns 68,284 shares of the company's stock, valued at $549,686.20. This represents a 4.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Christopher Sarchi sold 3,749 shares of the firm's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $8.05, for a total transaction of $30,179.45. Following the transaction, the insider now directly owns 128,296 shares in the company, valued at approximately $1,032,782.80. This trade represents a 2.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 74,907 shares of company stock valued at $603,655 over the last ninety days. 8.80% of the stock is owned by insiders.

Institutional Trading of Replimune Group

A number of institutional investors have recently made changes to their positions in REPL. Dimensional Fund Advisors LP increased its stake in shares of Replimune Group by 42.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 778,163 shares of the company's stock valued at $9,425,000 after purchasing an additional 232,822 shares in the last quarter. Nuveen Asset Management LLC lifted its stake in Replimune Group by 108.9% during the fourth quarter. Nuveen Asset Management LLC now owns 667,634 shares of the company's stock worth $8,085,000 after purchasing an additional 347,993 shares in the last quarter. Victory Capital Management Inc. acquired a new position in Replimune Group during the fourth quarter worth $543,000. Tower Research Capital LLC TRC raised its stake in shares of Replimune Group by 696.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock valued at $82,000 after acquiring an additional 5,922 shares in the last quarter. Finally, Swiss National Bank raised its stake in shares of Replimune Group by 57.4% in the fourth quarter. Swiss National Bank now owns 103,700 shares of the company's stock valued at $1,256,000 after acquiring an additional 37,800 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company's stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.